ArticleEBioMedicine2026
Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease features in resistance to thyroid hormone beta (RTHβ), caused by THRB mutations, arise from insensitivity to thyroid hormone in tissues expressing thyroid hormone receptor (TR)β and from lifelong thyrotoxic effects in TRα1-expressing tissues, posing substantial cardiovascular morbidity/mortality. The T3-analogue triiodothyroacetic acid (Triac) holds potential as an effective treatment. Systematic data on Triac therapy in RTHβ are lacking, and the mechanisms through which Triac acts are unclear. This study aims to elucidate these knowledge gaps.
methodsClinical and biochemical data were obtained through an, international retrospective cohort study in patients with RTHβ. Transcriptional activity of all TRβ mutants, on the background of the pituitary-expressed β2 receptor isoform and positively (DR+4-TRE) or negatively (TSHα-TRE) regulated reporter genes plus T3 or Triac, was studied. Thyroid function and TSH responses to T3 and Triac were tested in zebrafish expressing TRβ mutants.
findingsWe collected data from 28 patients with RTHβ (range: 0.4-73.1 years) with 18 unique mutations treated with Triac in 6 centres. Triac reduced TSH (by 43%) and FT4 (by 37%) concentrations in all heterozygous patients, supported by consistent findings in zebrafish. Our functional studies showed that TRβ2 mutants exhibited reduced (all) or absent (G432del) T3-dependent transcriptional activity, with similar EC50 and IC50 values for T3 and Triac, except for R316H, which showed a 5-times lower EC50/IC50 value for Triac compared to T3.
interpretationIn this international, multicentre study we have documented that Triac lowers elevated FT4 concentrations in patients with RTHβ effectively. Integrating our clinical and molecular observations we suggest that Triac can act via different modes of action, with activation of the wild-type receptor being a relevant mechanism. Our study may inform clinical management and could shape future interventional studies in patients with RTHβ.
fundingFinancial support is acknowledged by WL (Affiliated Hospital of Southwest Medical University) WEV (ZonMw (Dutch Research Council, VIDI 09150172210071)), KC (Wellcome (210755/Z/18/Z), NIHR Cambridge Biomedical Research Centre (NIHR20312) and Medical Research Council United Kingdom (MRC_MU_UU_00014/40)), LP (European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (code: PNRR-MR1-2022-12375726).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.